Evolv Technologies Holdings, Inc. filings document the public-company disclosures of an AI-based security screening business with Class A common stock and warrants listed on Nasdaq. Its Form 8-K reports include financial-results releases, Regulation FD disclosures, board and officer changes, stockholder meeting results, credit-agreement disclosures and registration-statement amendments tied to resale securities and warrant exercises.
Proxy materials describe director elections, executive compensation, auditor ratification, board committee matters and shareholder voting procedures. The filings also identify capital-structure elements, including Class A common stock, warrants and subsidiary borrowing arrangements, alongside governance and reporting matters for Evolv’s screening technology operations.
Evolv Technologies (EVLV) reported Q3 results showing faster growth and improved losses. Total revenue was $42.9 million, up from $27.4 million a year ago, led by subscription revenue of $22.7 million, service revenue of $7.8 million, product revenue of $9.2 million, and license/other revenue of $3.1 million. Gross profit rose to $21.3 million. The company posted a net loss of $1.8 million versus a $30.4 million loss last year, reflecting lower operating expenses and favorable fair value adjustments.
Liquidity improved with positive operating cash flow of $3.1 million for the nine months. Cash, cash equivalents, and marketable securities were $56.2 million as of September 30, 2025. Evolv entered a new $75.0 million senior secured credit facility, drawing $30.0 million, leaving $45.0 million available. Deferred revenue increased to $96.4 million, and annual recurring revenue was $117.2 million as of September 30, 2025. Shares outstanding were 174,617,589 as of November 7, 2025.
Evolv Technologies Holdings, Inc. reported that it announced financial results for the fiscal quarter ended September 30, 2025. The company furnished the full press release as Exhibit 99.1 to this Form 8-K.
The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.
Evolv Technologies Holdings (EVLV): Founder & Chief Growth Officer Anil Chitkara reported option exercises and open‑market sales. On 10/24/2025 and 10/27/2025, he exercised a total of 360,000 stock options at $0.24 and $0.42 per share and sold 360,000 Class A shares at a weighted average price of $8.20. The 10/24 sales occurred within $8.03–$8.34, and the 10/27 sale within $8.13–$8.30.
Following these transactions, he beneficially owned 1,275,100 shares directly. Option footnotes state one grant vested 25% on January 31, 2018 with 36 monthly installments thereafter, and another vested 25% on January 1, 2022 with 36 monthly installments thereafter.
Evolv Technologies Holdings (EVLV) reported a director’s Form 4 for transactions on 10/15/2025. The insider exercised 80,745 stock options at $0.24 and then sold 80,745 Class A shares at a $8.26 weighted average, with sales executed between $8.03 and $8.54, pursuant to a Rule 10b5-1 plan entered on June 12, 2025.
Following the transactions, the insider beneficially owned 2,083,961 shares directly and 151,135 shares indirectly (held by Family Horizon Trust), and held 1,542,974 derivative securities (stock options).
Gates Frontier, LLC and William H. Gates III reported beneficial ownership of 2,365,664 shares of Evolv Technologies Holdings, Inc. Class A common stock, representing 1.4% of the outstanding shares. The percent is calculated using 171,891,467 shares outstanding as of August 11, 2025, per the issuer's report. Gates Frontier is organized in Washington and WHG is a U.S. citizen. The filing states the shares were not acquired to influence control of the issuer and includes execution by an authorized attorney-in-fact dated September 22, 2025.
Michael Ellenbogen, Founder and Chief Innovation Officer of Evolv Technologies Holdings, Inc. (EVLV), reported transactions on 09/15/2025. He exercised 80,745 stock options with a $0.24 exercise price, resulting in acquisition of 80,745 Class A shares. On the same date he sold 80,745 Class A shares under a Rule 10b5-1 plan at a weighted average price of $8.46 per share (individual sale prices ranged $8.34–$8.80). Following the transactions, he reported 2,083,961 Class A shares held directly and 151,135 held indirectly by the Family Horizon Trust. The option expires 09/13/2027 and vested 25% on 01/31/2018 with subsequent monthly vesting; the Form 4 was signed by an attorney-in-fact on 09/17/2025.
Evolv Technologies Holdings, Inc. (EVLV) submitted a Form 144 disclosing a proposed sale of 242,235 Class A common shares through J.P. Morgan Securities LLC on 09/15/2025 on Nasdaq with an aggregate market value of $2,124,401. The filing shows these shares were acquired and paid for on 09/15/2025 via a stock option exercise and payment in cash. The filer reports 171,891,467 shares outstanding and states there were no sales in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Mark J. Sullivan, a director of Evolv Technologies Holdings, Inc. (EVLV), reported the vesting and issuance of 26,388 restricted stock units (RSUs) on September 2, 2025. Each RSU converts into one share of Class A common stock and vested in full on that date at no purchase price, increasing his beneficial ownership to 208,003 shares. The RSUs have no expiration date. The Form 4 was signed by an attorney-in-fact on September 3, 2025. All information is limited to the transactions and holdings disclosed on the form.
Data Collective IV, L.P. ("DC IV") and related reporting persons report beneficial ownership of 8,096,335 shares of Evolv Technologies Holdings, Inc. Class A Common Stock, representing 4.7% of the 171,891,467 shares outstanding used to calculate the percentage. The shares held by DC IV resulted from prior preferred-stock and convertible-note investments in Old Evolv that converted into issuer common stock in connection with the business combination described in the filing.
The filing discloses multiple open-market sales by DC IV, including sales on August 11–18, 2025 totaling 1,584,946 shares for aggregate reported proceeds of approximately $12,357,398.50. The reporting persons state the securities are held for general investment purposes and that they may buy or sell depending on market and other conditions. The filing also references the Registration Rights Agreement that governs resale and lock-up arrangements following the business combination.
Evolv Technologies Holdings reported that Stoic Point Capital Management and two individuals may beneficially own 5,396,901 shares of the issuer's Class A common stock, representing 3.1% of the outstanding Class A shares based on 171,891,467 shares outstanding. The reporting persons state the position cost approximately $13,847,006 and was funded from the working capital of private funds and separately managed accounts they manage. The holdings break down as 1,708,495 shares held by funds and 3,688,406 shares held by SMAs. The filing notes no other transactions in the past sixty days except as listed on an attached schedule.